Curing Pompe and Helping His Kids the Mission of Amicus CEO
Amicus' Opfolda wins positive CHMP opinion in Pompe Disease - Pharmaceutical Technology
Amicus Therapeutics Declares FDA Sanction and Introduction of Novel Therapy for Pompe Disease
New Pompe disease treatment 'exciting,' Amicus chairman says
Malattia di Pompe: approvata una nuova terapia nel Regno Unito - Osservatorio Malattie Rare
Amicus fail dents Pompe pipeline | Evaluate
Amicus drug for Pompe disease falls short in key clinical trial
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics' Pombiliti + Opfolda for Treatment of Pompe Disease | Muscular Dystrophy Association
FDA Extends Review Time for Pompe Disease Therapy
Bando: Opportunity to Spotlight Your Research in Pompe Disease
Amicus' muscle disorder therapy gets US FDA nod but restricted label drags shares | SaltWire
UK approval for Pompe Disease therapy
European Commission approves Amicus Therapeutics' Pompe disease therapy - PMLiVE
Amicus gears up to launch Pompe disease combination therapy in the UK - Pharmaceutical Technology
Amicus takes walk-test outcome in stride as Pompe BLA rolls on | 2021-02-12 | BioWorld
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union - Canadian Association of Pompe
Amicus' Pompe approval portends a showdown with Sanofi
MHRA marketing authorization granted to Amicus' Pompe disease treatment
Amicus's new drug for Pompe disease shows strong results
John Crowley, Amicus Therapeutics, discusses drug trial results for Pompe disease
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease | Amicus Therapeutics
FDA approves Amicus' combination therapy for LOPD
